Percutaneous Coronary Intervention Using the DynamX Sirolimus-Eluting Bioadaptor: 12-Month Clinical and Imaging Outcomes

IF 1.6 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of interventional cardiology Pub Date : 2024-10-17 DOI:10.1155/2024/8876443
Mark Webster, Douglas Scott, Madhav Menon, Dougal McClean, Seif El-Jack, Gerard Wilkins, Scott A. Harding
{"title":"Percutaneous Coronary Intervention Using the DynamX Sirolimus-Eluting Bioadaptor: 12-Month Clinical and Imaging Outcomes","authors":"Mark Webster,&nbsp;Douglas Scott,&nbsp;Madhav Menon,&nbsp;Dougal McClean,&nbsp;Seif El-Jack,&nbsp;Gerard Wilkins,&nbsp;Scott A. Harding","doi":"10.1155/2024/8876443","DOIUrl":null,"url":null,"abstract":"<div>\n <p>The DynamX Bioadaptor is a novel implant with uncaging elements that disengage after polymer resorption and permits restoration of vessel function, thereby potentially reducing late adverse cardiac events. We evaluated the safety and efficacy of this novel implant with imaging follow-up at 6-months, the time point when the bioadaptor starts to uncage. This prospective study enrolled 44 patients with up to two de novo lesions at seven centers in New Zealand treated with the DynamX Bioadaptor. Follow-up was planned out to 12-months. The primary safety and efficacy endpoints were 6-month target lesion failure (TLF) and late lumen loss. Patients presented with non-ST elevation myocardial infarction in 49%. Lesions (<i>n</i> = 45) were 16.0 ± 6.7 mm long, and 2.81 ± 0.41 mm in diameter. Device and procedure success were 100%, and acute lumen gain was 1.93 ± 0.35 mm. At 6-months, median in-device late lumen loss was 0.09 mm (IQR:0.05–0.16). Measured by intravascular ultrasound, the vessel, lumen, and device area remained constant. By optical coherence tomography, 96.4% ± 5.9% of struts per lesion were covered. Out to 12-months, no TLF and no definite or probable device thrombosis were reported. In conclusion, this study provides evidence of the safety and performance of the DynamX Bioadaptor with excellent 12-month clinical and 6-month imaging outcomes comparable to best-in-class drug-eluting stents (DES).</p>\n <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT03634020, NCT05464147, NCT04562805, and NCT04192747.</p>\n </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8876443","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of interventional cardiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/8876443","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

The DynamX Bioadaptor is a novel implant with uncaging elements that disengage after polymer resorption and permits restoration of vessel function, thereby potentially reducing late adverse cardiac events. We evaluated the safety and efficacy of this novel implant with imaging follow-up at 6-months, the time point when the bioadaptor starts to uncage. This prospective study enrolled 44 patients with up to two de novo lesions at seven centers in New Zealand treated with the DynamX Bioadaptor. Follow-up was planned out to 12-months. The primary safety and efficacy endpoints were 6-month target lesion failure (TLF) and late lumen loss. Patients presented with non-ST elevation myocardial infarction in 49%. Lesions (n = 45) were 16.0 ± 6.7 mm long, and 2.81 ± 0.41 mm in diameter. Device and procedure success were 100%, and acute lumen gain was 1.93 ± 0.35 mm. At 6-months, median in-device late lumen loss was 0.09 mm (IQR:0.05–0.16). Measured by intravascular ultrasound, the vessel, lumen, and device area remained constant. By optical coherence tomography, 96.4% ± 5.9% of struts per lesion were covered. Out to 12-months, no TLF and no definite or probable device thrombosis were reported. In conclusion, this study provides evidence of the safety and performance of the DynamX Bioadaptor with excellent 12-month clinical and 6-month imaging outcomes comparable to best-in-class drug-eluting stents (DES).

Trial Registration: ClinicalTrials.gov identifier: NCT03634020, NCT05464147, NCT04562805, and NCT04192747.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用 DynamX Sirolimus 洗脱生物适配器进行经皮冠状动脉介入治疗:12 个月的临床和成像结果
DynamX 生物适配器是一种新型植入物,它具有可在聚合物吸收后脱离的解笼元件,允许恢复血管功能,从而可能减少后期不良心脏事件。我们对这种新型植入物的安全性和有效性进行了评估,并在生物适配器开始松开的 6 个月后进行了成像随访。这项前瞻性研究在新西兰的 7 个中心招募了 44 名接受 DynamX 生物适配器治疗的患者,这些患者最多有两个新发病灶。计划随访 12 个月。主要的安全性和有效性终点是6个月靶病变失败(TLF)和晚期管腔缺损。49%的患者出现非ST段抬高型心肌梗死。病变(n = 45)长度为 16.0 ± 6.7 毫米,直径为 2.81 ± 0.41 毫米。设备和手术成功率均为 100%,急性管腔增宽为 1.93 ± 0.35 毫米。6个月后,装置内晚期管腔损失的中位数为0.09毫米(IQR:0.05-0.16)。通过血管内超声测量,血管、管腔和装置面积保持不变。通过光学相干断层扫描,每个病变的支架覆盖率为 96.4% ± 5.9%。术后 12 个月内,无 TLF 报告,无明确或可能的装置血栓形成。总之,这项研究证明了 DynamX Bioadaptor 的安全性和性能,其 12 个月的临床和 6 个月的成像结果与同类最佳药物洗脱支架 (DES) 不相上下。 试验注册:临床试验注册:ClinicalTrials.gov identifier:NCT03634020、NCT05464147、NCT04562805 和 NCT04192747。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of interventional cardiology
Journal of interventional cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.80
自引率
0.00%
发文量
81
审稿时长
6-12 weeks
期刊介绍: Journal of Interventional Cardiology is a peer-reviewed, Open Access journal that provides a forum for cardiologists determined to stay current in the diagnosis, investigation, and management of patients with cardiovascular disease and its associated complications. The journal publishes original research articles, review articles, and clinical studies focusing on new procedures and techniques in all major subject areas in the field, including: Acute coronary syndrome Coronary disease Congenital heart diseases Myocardial infarction Peripheral arterial disease Valvular heart disease Cardiac hemodynamics and physiology Haemostasis and thrombosis
期刊最新文献
A Comparative Analysis of Primary and Bailout ADR in CTO-PCI The Effect of Electromagnetic Interference Produced by Smartphones Using 5G Network on Patients With Permanent Pacemakers (EMS5G-PPM Study) Comparison of Sheathless and Sheathed Guiding Catheters in Transradial Percutaneous Coronary Interventions: A Systematic Review and Meta-Analysis Percutaneous Coronary Intervention Using the DynamX Sirolimus-Eluting Bioadaptor: 12-Month Clinical and Imaging Outcomes Vascular Complications and Bleeding After Transfemoral TAVR With Surgical Versus Percutaneous Approach: A Contemporary Prospective Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1